THE FORUM
For Collaborative Research℠

Specific Topics Panels: Panel 3 - Data Quality in Outcome Assessments

Mary Lin, *CBER, FDA*

Berkeley Public Health

Study flow: treatment phase



Subject disposition

Screened	**107**
Not meet eligibility criteria Apheresis product not accepted at manufacturing facility Death Screening date after data cutoff	12 1 2 4
Enrolled	**88 (100%)**
Manufacturing failure	8* (9%)
Death	9*(10%)
Adverse event	2 (2%)
Infusion pending	4 (5%)
Full analysis set	**68**
Subjects treated with products manufactured in Germany	5
Efficacy analysis set	63

* 3 subjects counted twice, they died and their product did not successfully manufactured.

Efficacy results based on different analysis population

	Enrolled Set (n=88)	Modified Enrolled Set* (n=78)	Efficacy analysis Set (n=63)
ORR (95% CI)	59.1% (48.1, 69.5)	66.7% (55.1, 76.9)	82.5% (70.9, 91.0)
CR	45.5%	54.8%	63%
CRi	13.6%	16.4%	19%

* subjects who were enrolled and their apheresis products were accepted at the U.S. facility.

Overall Treatment Experience for each subject



Ventilation Support Hours for each subject



Developmental Milestones Achieved for each subject